A Phase 1/2 interventional study of meropenem in Necrotizing Enterocolitis and Intra-abdominal Infection, sponsored by The Emmes Company, LLC. Completed at 26 sites in United States. Open to participants aged Up to 90 Days. Per ClinicalTrials.gov, last updated 2023-04-25.
Sponsored by The Emmes Company, LLC · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 62 studies in Enterocolitis, Necrotizing with a site in United States — 5 open to participants now, 8 under way, 1 of them phase 3. Enterocolitis, Necrotizing · United States.
Among the 62 studies in Enterocolitis, Necrotizing with a site in United States, this one is the 7th largest by enrollment of the 36 interventional ones that give a count, is one of 4 that started in 2008, is one of 4 in phase 1/2, and was the 12th registered.
229 studies on the registry are indexed under Enterocolitis, Necrotizing; 45 are open to participants now.
Browse Enterocolitis, Necrotizing studies →5 of the 62 studies in Enterocolitis, Necrotizing with a site in United States are open now. Recruiting first, the newest first:
University of Maryland, Baltimore · Sites in United States
Ages up to 4 days
Boston Children's Hospital · Sites in United States
Ages up to 2
Noveome Biotherapeutics, formerly Stemnion · Sites in United States
Ages 2 wk–8 wk
Eclipse Regenesis, Inc. · Sites in United States
Ages 3 mo–65 yrs
University of Utah · Sites in United States
Ages up to 1 hrs · Healthy volunteers
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 26 Enterocolitis, Necrotizing studies recruiting now, 4 (15%) set no upper age limit and 22 (85%) stop at 75 or younger; 26 take children under 18; 3 take healthy volunteers.
This study: Up to 90 Days · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
62 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 10 · Phase 2 12 · Phase 3 4
First in 1993; this study’s year is marked. 4 started in 2008.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 200 is above the median of 106 across 128 interventional studies indexed under Enterocolitis, Necrotizing.
Median enrollment 79 across the 36 interventional studies, 111 across the 26 observational. Of the 43 that completed or were terminated, 17 (40%) have results posted.
This tab as a report to print or save as PDF → With an account.
7 of 62 have an industry lead sponsor. The 10 most frequent:
The Emmes Company, LLC is the lead sponsor of 11 studies on the registry; none are open to participants now.
The Emmes Company, LLC has 1 study filed under Enterocolitis, Necrotizing — fewer than ten, so there is no comparison to draw.
3 of the studies in Enterocolitis, Necrotizing with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03210831Nationwide Children's HospitalEarly Predictors of Necrotizing Enterocolitis in Neonates | 2026-12 |
| NCT03717584University of California, DavisA Cohort Study of the Intestinal Microbiota of Premature Infants | 2027-03-05 |
| NCT07667049University of Maryland, BaltimoreGut Permeability and Microbiome in Preterm Infants | 2027-10-30 |
Add all 3 to your calendar (.ics) → With an account.
Among the 62 studies in Enterocolitis, Necrotizing with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Meropenem is an antibiotic that is commonly used to treat serious infections. Although it is used in premature and young infants, the correct dose is not known. The purpose of this study is to determine the correct dose and the safety of meropenem for the treatment of complicated intra-abdominal infections in these young babies.
This study will evaluate the safety, tolerability and Pharmacokinetics - Pharmacodynamics (PK-PD) of meropenem in infants \<91 days of age with suspected and complicated intra-abdominal infections.
The specific aims of this trial are:
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Sufficient intravascular access (either peripheral or central) to receive study drug.
AND ONE OF THE FOLLOWING
OR 2) Possible NEC OR 3) Otherwise receiving meropenem per local standard of care
Exclusion criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
These Participants were subdivided into the following four groups based on Gestational Age (GA) and Postnatal Age (PNA): Group 1: GA at birth below 32 weeks - PNA \<2 weeks; Group 2: GA at birth below 32 weeks - PNA ≥2 weeks and \<91 days; Group 3: GA at birth 32 weeks or older - PNA \<2 weeks; Group 4: GA at birth 32 weeks or older - PNA ≥2 weeks and \<91 days.
Drug: meropenem
Meropenem was administered concomitantly with compatible medications. Because an in-line filter is not appropriate due to drug binding, the 30 minute infusion was rate controlled by using appropriate infusion (syringe) pumps. Dosing and administration of other antimicrobial therapy (e.g., an aminoglycoside) was administered per local standard of care at the discretion of the infant's neonatologist. If there was a delay in the study drug shipment, sites were to use open-label meropenem to protect the safety of the participant. 20 mg/kg every 12 hours in infants \<32 weeks GA and PNA \< 2 weeks 20 mg/kg every 8 hours in infants \<32 weeks GA and PNA ≥ 2 weeks 20 mg/kg every 8 hours in infants ≥32 weeks GA and PNA \< 2 weeks 30 mg/kg every 8 hours in infants ≥32 weeks GA and PNA ≥ 2 weeks
Also known as: Merrem
Efficacy Success (Alive at Efficacy Visit,Last Culture (if Obtained) From Sterile Body Fluid is Negative for Bacteria (Except Staphylococcus Species) From Start of Study Drug Until Efficacy Visit,Presumptive Clinical Cure Score(PCCS) >7 at Efficacy Visit)
The PCCS was derived by comparing clinical signs and symptoms prior to administration of the first dose of study drug and study Day 28.The elements of the PCCS include Mean BP,Temp,PaO2(mmHg)/FiO2,Lowest serum pH,seizures,Urine output,Cardiovascular inotrope support,C-reactive protein (CRP)and Abdominal girth. Score - Asymptomatic to Asymptomatic 1;Asymptomatic to Worsening 0;Symptomatic to Worsening 0;Symptomatic to No change 0;Symptomatic to Improved 1;Symptomatic to Asymptomatic 1 If 7 or more of 10 signs received a score of 1, then the infant was considered a presumptive clinical cure. GA stands for Gestational Age and PNA stands for Postnatal Age.
Time frame: Average of 12 days (3 to 21 days)
Deaths
Time frame: Up to 51 days (Recorded from the time of informed consent until 72 hours following the last dose of study drug)
Meropenem Clearance
Given the limited availability of blood for Pharmacokinetic (PK) assessments in this population a sparse sampling approach was utilized. Subjects were assigned to one of two Dose 1 sample collection schedules, "PK-odd" and "PK-even" based on birth date to ensure collection of PK data throughout the dose interval. In addition, PK samples were collected around approximately the 5th dose. Subjects that did not have Dose 1 PK samples could have steady-state (Dose 5) using the Dose 5 PK collection schedule.
Time frame: Up to 7-8hrs post drug administration
Key Safety Endpoints
Safety assessments included death, seizure documentation (including correlation of serum meropenem level and seizures), strictures, perforation, wound dehiscence, short gut, development of extended beta lactamase infection, development of candidiasis, antimicrobial therapy failure
Time frame: Up to 51 days (Adverse Events (AEs) were recorded from the time of informed consent until 72 hours following the last dose of study drug)
Enrollment Period - June 19, 2008 to October 6, 2009 Locations - Hospitals including University Hospitals Total number of sites - 24 Total number of participants - 200
| Milestone | 1. GA <32 Wks; PNA<2 Wks | 2. GA <32 Wks; PNA 91days ≥ 2Wks | 3. GA ≥ 32 Wks; PNA <2 Wks | 4. GA ≥32 Wks; PNA 91 Days ≥ 2 Wks |
|---|---|---|---|---|
| Started | 39 | 103 | 31 | 27 |
| Safety population | 39 | 103 | 31 | 27 |
| Efficacy population | 39 | 101 | 28 | 27 |
| Completed | 35 | 94 | 26 | 24 |
| Not completed | 4 | 9 | 5 | 3 |
| Withdrew: Withdrawal by subject | 0 | 0 | 2 | 0 |
| Withdrew: Physician decision | 1 | 3 | 0 | 0 |
| Withdrew: Protocol violation | 1 | 0 | 0 | 1 |
| Withdrew: Adverse event | 0 | 1 | 0 | 1 |
| Withdrew: Death | 2 | 5 | 0 | 0 |
| Withdrew: Final assessments not completed | 0 | 0 | 3 | 1 |
The PCCS was derived by comparing clinical signs and symptoms prior to administration of the first dose of study drug and study Day 28.The elements of the PCCS include Mean BP,Temp,PaO2(mmHg)/FiO2,Lowest serum pH,seizures,Urine output,Cardiovascular inotrope support,C-reactive protein (CRP)and Abdominal girth. Score - Asymptomatic to Asymptomatic 1;Asymptomatic to Worsening 0;Symptomatic to Worsening 0;Symptomatic to No change 0;Symptomatic to Improved 1;Symptomatic to Asymptomatic 1 If 7 or more of 10 signs received a score of 1, then the infant was considered a presumptive clinical cure. GA stands for Gestational Age and PNA stands for Postnatal Age.
| Participants | 1. GA <32 Wks; PNA<2 Wks | 2. GA <32 Wks; PNA 91days ≥ 2Wks | 3. GA ≥ 32 Wks; PNA <2 Wks | 4. GA ≥32 Wks; PNA 91 Days ≥ 2 Wks |
|---|---|---|---|---|
| Efficacy Success (Alive at Efficacy Visit,Last Culture (if Obtained) From Sterile Body Fluid is Negative for Bacteria (Except Staphylococcus Species) From Start of Study Drug Until Efficacy Visit,Presumptive Clinical Cure Score(PCCS) >7 at Efficacy Visit) | 29 | 82 | 26 | 25 |
| Participants | 1. GA <32 Wks; PNA<2 Wks | 2. GA <32 Wks; PNA 91days ≥ 2Wks | 3. GA ≥ 32 Wks; PNA <2 Wks | 4. GA ≥32 Wks; PNA 91 Days ≥ 2 Wks |
|---|---|---|---|---|
| Deaths | 3 | 8 | 0 | 0 |
Given the limited availability of blood for Pharmacokinetic (PK) assessments in this population a sparse sampling approach was utilized. Subjects were assigned to one of two Dose 1 sample collection schedules, "PK-odd" and "PK-even" based on birth date to ensure collection of PK data throughout the dose interval. In addition, PK samples were collected around approximately the 5th dose. Subjects that did not have Dose 1 PK samples could have steady-state (Dose 5) using the Dose 5 PK collection schedule.
| L/h/kg | 1. GA <32 Wks; PNA<2 Wks | 2. GA <32 Wks; PNA 91days ≥ 2Wks | 3. GA ≥ 32 Wks; PNA <2 Wks | 4. GA ≥32 Wks; PNA 91 Days ≥ 2 Wks |
|---|---|---|---|---|
| Meropenem Clearance | 0.089 ± 0.027 | 0.122 ± 0.037 | 0.135 ± 0.040 | 0.202 ± 0.061 |
Safety assessments included death, seizure documentation (including correlation of serum meropenem level and seizures), strictures, perforation, wound dehiscence, short gut, development of extended beta lactamase infection, development of candidiasis, antimicrobial therapy failure
| Participants | 1. GA <32 Wks; PNA<2 Wks | 2. GA <32 Wks; PNA 91days ≥ 2Wks | 3. GA ≥ 32 Wks; PNA <2 Wks | 4. GA ≥32 Wks; PNA 91 Days ≥ 2 Wks |
|---|---|---|---|---|
| Death | 3 (1.6% to 20.9%) | 8 | 0 | 0 |
| Seizure | 4 | 3 | 1 | 2 |
| Strictures | 0 | 0 | 0 | 0 |
| Perforation | 2 | 2 | 0 | 0 |
| Wound Dehiscence | 1 | 1 | 1 | 1 |
| Development of Candidiasis | 5 | 3 | 0 | 0 |
| Antimicrobial Therapy Failure | 7 | 12 | 2 | 2 |
Collected over Adverse Events (AEs) were recorded from the time of informed consent until 72 hours following the last dose of study drug for non-Serious Adverse Events (SAEs) and until 30 days after the last dose of study drug for SAEs.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| 1. GA <32 Wks; PNA<2 Wks | — | 9/39 (23.1%) | 9/39 (23.1%) |
| 2. GA <32 Wks; PNA 91days ≥ 2Wks | — | 18/103 (17.5%) | 8/103 (7.8%) |
| 3. GA ≥ 32 Wks; PNA <2 Wks | — | 2/31 (6.5%) | 2/31 (6.5%) |
| 4. GA ≥32 Wks; PNA 91 Days ≥ 2 Wks | — | 5/27 (18.5%) | 3/27 (11.1%) |
| Event | 1. GA <32 Wks; PNA<2 Wks | 2. GA <32 Wks; PNA 91days ≥ 2Wks | 3. GA ≥ 32 Wks; PNA <2 Wks | 4. GA ≥32 Wks; PNA 91 Days ≥ 2 Wks |
|---|---|---|---|---|
| Intestinal perforationGastrointestinal disorders | 2/39 | 2/103 | 0/31 | 0/27 |
| Necrotising ColitisGastrointestinal disorders | 2/39 | 1/103 | 0/31 | 0/27 |
| Multi-organ failureGeneral disorders | 2/39 | 2/103 | 0/31 | 0/27 |
| Patent Ductus ArteriosusCongenital, familial and genetic disorders | 0/39 | 0/103 | 0/31 | 1/27 |
| Intestinal ObstructionGastrointestinal disorders | 0/39 | 0/103 | 0/31 | 1/27 |
| Intestinal StenosisGastrointestinal disorders | 0/39 | 0/103 | 0/31 | 1/27 |
| Chest X-Ray AbnormalInvestigations | 0/39 | 0/103 | 0/31 | 1/27 |
| Pneumonia AspirationRespiratory, thoracic and mediastinal disorders | 0/39 | 0/103 | 0/31 | 1/27 |
| Respiratory DistressRespiratory, thoracic and mediastinal disorders | 0/39 | 0/103 | 0/31 | 1/27 |
| Rectal HaemorrhageGastrointestinal disorders | 0/39 | 0/103 | 1/31 | 0/27 |
| Event | 1. GA <32 Wks; PNA<2 Wks | 2. GA <32 Wks; PNA 91days ≥ 2Wks | 3. GA ≥ 32 Wks; PNA <2 Wks | 4. GA ≥32 Wks; PNA 91 Days ≥ 2 Wks |
|---|---|---|---|---|
| SepsisInfections and infestations | 5/39 | 5/103 | 1/31 | 1/27 |
| ConvulsionNervous system disorders | 4/39 | 3/103 | 1/31 | 2/27 |
| Age, Continuous(Days) | 1. GA <32 Wks; PNA<2 Wks | 2. GA <32 Wks; PNA 91days ≥ 2Wks | 3. GA ≥ 32 Wks; PNA <2 Wks | 4. GA ≥32 Wks; PNA 91 Days ≥ 2 Wks | Total |
|---|---|---|---|---|---|
| Mean Postnatal Age | 8.5 ± 3.3 | 38.3 ± 19.3 | 6.5 ± 3.5 | 36.0 ± 22.0 | 27.3 ± 21.6 |
| Sex: Female, Male(Participants) | 1. GA <32 Wks; PNA<2 Wks | 2. GA <32 Wks; PNA 91days ≥ 2Wks | 3. GA ≥ 32 Wks; PNA <2 Wks | 4. GA ≥32 Wks; PNA 91 Days ≥ 2 Wks | Total |
|---|---|---|---|---|---|
| Female | 15 | 47 | 9 | 11 | 82 |
| Male | 24 | 56 | 22 | 16 | 118 |
| Ethnicity (NIH/OMB)(Participants) | 1. GA <32 Wks; PNA<2 Wks | 2. GA <32 Wks; PNA 91days ≥ 2Wks | 3. GA ≥ 32 Wks; PNA <2 Wks | 4. GA ≥32 Wks; PNA 91 Days ≥ 2 Wks | Total |
|---|---|---|---|---|---|
| Hispanic or Latino | 5 | 16 | 4 | 3 | 28 |
| Not Hispanic or Latino | 32 | 81 | 27 | 24 | 164 |
| Unknown or Not Reported | 2 | 6 | 0 | 0 | 8 |
| Race (NIH/OMB)(Participants) | 1. GA <32 Wks; PNA<2 Wks | 2. GA <32 Wks; PNA 91days ≥ 2Wks | 3. GA ≥ 32 Wks; PNA <2 Wks | 4. GA ≥32 Wks; PNA 91 Days ≥ 2 Wks | Total |
|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 |
| Asian | 0 | 1 | 0 | 1 | 2 |
| Native Hawaiian or Other Pacific Islander | 1 | 0 | 1 | 0 | 2 |
| Black or African American | 12 | 33 | 8 | 5 | 58 |
| White | 25 | 65 | 21 | 18 | 129 |
| More than one race | 1 | 2 | 0 | 2 | 5 |
| Unknown or Not Reported | 0 | 2 | 1 | 1 | 4 |
The record gives a start of Jun 2008, a primary completion of Oct 2009 and a completion of Oct 2009. It does not say whether these dates are actual or estimated.
Results were first posted in Nov 2011, 2 years 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Meropenem
The Emmes Company, LLC